EP1578996A4 - Zusammensetzungen und verfahren für die tumor-diagnose und behandlung - Google Patents

Zusammensetzungen und verfahren für die tumor-diagnose und behandlung

Info

Publication number
EP1578996A4
EP1578996A4 EP03813488A EP03813488A EP1578996A4 EP 1578996 A4 EP1578996 A4 EP 1578996A4 EP 03813488 A EP03813488 A EP 03813488A EP 03813488 A EP03813488 A EP 03813488A EP 1578996 A4 EP1578996 A4 EP 1578996A4
Authority
EP
European Patent Office
Prior art keywords
tumor
diagnosis
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03813488A
Other languages
English (en)
French (fr)
Other versions
EP1578996A2 (de
Inventor
Thomas D Wu
Yan Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of EP1578996A2 publication Critical patent/EP1578996A2/de
Publication of EP1578996A4 publication Critical patent/EP1578996A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
EP03813488A 2002-10-18 2003-10-15 Zusammensetzungen und verfahren für die tumor-diagnose und behandlung Withdrawn EP1578996A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41898802P 2002-10-18 2002-10-18
US418988P 2002-10-18
PCT/US2003/029126 WO2004060270A2 (en) 2002-10-18 2003-10-15 Compositions and methods for the diagnosis and treatment of tumor

Publications (2)

Publication Number Publication Date
EP1578996A2 EP1578996A2 (de) 2005-09-28
EP1578996A4 true EP1578996A4 (de) 2007-12-19

Family

ID=32712943

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03813488A Withdrawn EP1578996A4 (de) 2002-10-18 2003-10-15 Zusammensetzungen und verfahren für die tumor-diagnose und behandlung

Country Status (5)

Country Link
EP (1) EP1578996A4 (de)
JP (1) JP2006516192A (de)
AU (1) AU2003303144A1 (de)
CA (1) CA2503043A1 (de)
WO (1) WO2004060270A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1468118A4 (de) * 2002-01-31 2006-08-02 Millennium Pharm Inc Verfahren und zusammensetzungen zur behandlung von krebs
EP1562969A4 (de) * 2002-03-28 2006-07-05 Bristol Myers Squibb Co Neues menschliches zelloberglächenprotein mit immunglobulinfaltunfen, bgs-19
WO2003091402A2 (en) * 2002-04-23 2003-11-06 University Of Georgia Research Foundation, Inc. N-ACETYLGLUCOSAMINYLTRANSFERASE Vb CODING SEQUENCE, RECOMBINANT CELLS AND METHODS
EP1584684A1 (de) * 2004-02-20 2005-10-12 Samsung Electronics Co., Ltd. Brustkrebs-verwandtes Protein, hierfür codierendes Gen und Methode zur Diagnose von Brustkrebs unter Verwendung des Proteins und Gens
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
MX2007002043A (es) 2004-08-16 2007-10-11 Quark Biotech Inc Usos terapeuticos de los inhibidores del rtp801.
GB0422211D0 (en) * 2004-10-06 2004-11-03 Randox Lab Ltd Method
US20080145369A1 (en) * 2004-10-13 2008-06-19 Ginette Serrero Autocrine Growth Factor Receptors and Methods
JP2007008844A (ja) * 2005-06-29 2007-01-18 Nippon Flour Mills Co Ltd セプチン２タンパク質と特異的に反応するモノクローナル抗体、それを産生するハイブリドーマ、癌の検出方法及び癌の検出用キット
UY30097A1 (es) 2006-01-20 2007-08-31 Atugen Ag Usos terapeuticos de inhibidores de rtp801
US20070237713A1 (en) 2006-04-04 2007-10-11 Fan Rong A PCan065 Antibody Compositions and Methods of Use
WO2008054534A2 (en) 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Screening systems utilizing rtp801
IL282783B2 (en) * 2006-05-18 2023-09-01 Caris Mpi Inc A system and method for determining a personalized medical intervention for a disease stage
WO2007141796A2 (en) 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
WO2008106102A2 (en) 2007-02-26 2008-09-04 Quark Pharmaceuticals, Inc. Inhibitors of rtp801 and their use in disease treatment
US20100196898A1 (en) * 2007-05-24 2010-08-05 The Brigham & Women's Hospital, Inc. Disease-associated genetic variations and methods for obtaining and using same
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
WO2010023856A1 (en) * 2008-08-27 2010-03-04 Oncotherapy Science, Inc. Pancreatic cancer related gene ttll4
JP5808254B2 (ja) 2009-02-20 2015-11-10 ガニメド ファーマシューティカルズ アーゲー 癌の診断および治療のための方法および組成物
SG10202110692WA (en) 2009-11-11 2021-12-30 Ganymed Pharmaceuticals Gmbh Antibodies specific for claudin 6 (cldn6)
WO2011150400A1 (en) * 2010-05-28 2011-12-01 New York Blood Center, Inc. Nuclear scaffold protein stip/tfip11 target for cancer therapy
EP2404936A1 (de) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Krebstherapie mittels CLDN6-zielgerichteter Antikörper im lebenden Organismus
CN103748112B (zh) 2011-05-13 2017-02-15 加尼梅德药物公司 用于治疗表达密蛋白6之癌症的抗体
SG11201503567SA (en) 2012-12-05 2015-06-29 Novartis Ag Compositions and methods for antibodies targeting epo
RS57316B1 (sr) * 2013-03-15 2018-08-31 Translate Bio Inc Sinergističko poboljšanje isporuke nukleinskih kiselina pomoću mešavina formulacija
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
EP3334842B1 (de) 2015-08-12 2022-03-02 Novartis AG Verfahren zur behandlung von augenerkrankungen
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US20210145946A1 (en) 2017-01-24 2021-05-20 Thoeris Gmbh Use of glutamine synthetase for treating hyperammonemia
JP2022186461A (ja) * 2021-06-04 2022-12-15 地方独立行政法人東京都健康長寿医療センター 前立腺がん治療用医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8678501A (en) * 2000-08-24 2002-03-04 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
EP1445317A3 (de) * 2000-08-24 2004-12-15 Genentech Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Krebs
WO2002016581A2 (en) * 2000-08-24 2002-02-28 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL/GENBANK/DDBJ 13 June 2001 (2001-06-13), STRAUSBERG, R.L. ET AL: "Homo sapiens papillary renal cell carcinoma", XP002446467, retrieved from EBI Database accession no. BC010450 *
WETERMAN MARIAN A J ET AL: "Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1) (p11;q21)-positive papillary renal cell carcinomas", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 93, no. 26, 1996, pages 15294 - 15298, XP002446464, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
JP2006516192A (ja) 2006-06-29
WO2004060270A2 (en) 2004-07-22
EP1578996A2 (de) 2005-09-28
CA2503043A1 (en) 2004-07-22
WO2004060270A8 (en) 2005-07-14
AU2003303144A1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
EP1571968A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren
EP1589933A4 (de) Zusammensetzungen und verfahren für dietumor-diagnose und behandlung
EP1572091A4 (de) Zusammensetzungen und verfahren für die tumordiagnose und behandlung
EP1553912A4 (de) Zusammensetzungen und verfahren f r die tumordiagnose und behandlung
EP1578996A4 (de) Zusammensetzungen und verfahren für die tumor-diagnose und behandlung
WO2004030615A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A3 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1575571A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung eines tumors
EP1572091A3 (de) Zusammensetzungen und verfahren für die tumordiagnose und behandlung
AU2003302892A8 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EP1575480A4 (de) Zusammensetzungen und verfahren zur behandlung von immunbedingten erkrankungen
EP1578367A4 (de) Zusammensetzungen und verfahren zur behandlung von immunerkrankungen
EP1572116A4 (de) Zusammensetzungen und verfahren für die behandlung von immunkrankheiten
EP1576137A4 (de) Zusammensetzungen und verfahren für die behandlung von immunkrankheiten
HK1086488A1 (en) Compound and use thereof for the treatment of cancer
IL162201A0 (en) New methods for diagnosis and treatment of tumours
EP1551990A4 (de) Diagnose und behandlung chemoresistenter tumoren
AU2003300368A8 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
EP1516049A4 (de) Zusammensetzungen und verfahren für die therapie und diagnose von lungenkrebs
AU2003290605A8 (en) Compositions and methods for the diagnosis and treatment of sepsis
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
ZA200510282B (en) Compositions and methods for the diagnosis and treatment of tumor
EP1446013A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050425

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ZHOU, YAN

Inventor name: WU, THOMAS, D.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GENENTECH, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20071119

17Q First examination report despatched

Effective date: 20080728

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090210